Skip to main content

Glofitamab

Generic name: glofitamab [ gloe-FIT-a-mab ]
Brand name: Columvi
Dosage form: intravenous solution (gxbm 1 mg/mL)
Drug class: Bispecific T-cell engagers (BiTE)

Medically reviewed by Drugs.com on Oct 23, 2023. Written by Cerner Multum.

What is glofitamab?

Glofitamab is used to treat certain types of lymphoma in adults whose cancer has returned or did not respond to another treatment and who have received at least two previous cancer treatments.

Glofitamab may also be used for purposes not listed in this medication guide.

Glofitamab side effects

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Tell your medical caregivers if you have signs of cytokine release syndrome (CRS), a serious side effect: fever, chills, trouble breathing, confusion, severe vomiting or diarrhea, fast or irregular heartbeats, feeling light-headed or very tired.

Glofitamab may cause serious side effects. Call your doctor at once if you have:

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of glofitamab may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

Tell your medical caregivers if you have symptoms of a serious side effect, such as fever, chills, trouble breathing, vomiting, or severe tiredness.

Before taking this medicine

Tell your doctor if you have:

May harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use effective birth control while using glofitamab and for at least 1 month after your last dose. Tell your doctor right away if you are pregnant or plan to become pregnant.

Do not breastfeed while using glofitamab, and for at least 1 month after your last dose.

How is glofitamab given?

Read the Patient Wallet Card about serious side effects and learn what symptoms to watch for. Keep the card with you at all times.

Glofitamab is given as an infusion into a vein. A healthcare provider will give you this injection.

Glofitamab is given in a 21-day treatment cycle. You will receive an injection only on certain days of this cycle.

This medicine is given slowly, and the infusion can take up to 8 hours to complete.

You may be given other medications to help prevent serious side effects or allergic reaction. Keep taking these medicines for as long as your doctor has prescribed.

Your healthcare provider will check for cytokine Release Syndrome (CRS) while you are being treated and may treat you in a hospital if you develop signs and symptoms of CRS.

You will need frequent medical tests, and your next dose may be delayed based on the results.

prednisone, rituximab, cyclophosphamide, Rituxan, doxorubicin, Cytoxan

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your glofitamab injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while receiving glofitamab?

Avoid driving or hazardous activity until you know how glofitamab will affect you. Your reactions could be impaired.

What other drugs will affect glofitamab?

Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.

Other drugs may affect glofitamab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Does glofitamab interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Glofitamab Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for glofitamab.

Columvi (glofitamab-gxbm) - Genentech, Inc.
Formulation type Strength
Single-Dose Vial 10 mg/10 mL (1 mg/mL)
Single-Dose Vial 2.5 mg/2.5 mL (1 mg/mL)

View Columvi information in detail.

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.